Filing Flows › Companies › BioScience Health Innovations › Cash flow
BioScience Health Innovations cash flow, quarter by quarter
Latest: Q2 2026 · from the cash-flow statements filed with the SEC
Free cash flow−$542K in Q2 2026 · −$1.5M over twelve months
Analysis
In Q2 2026, BioScience Health Innovations generated −$542K of operating cash flow. That is $827K less than in Q2 2025 ($285K).
Over the twelve months to Jun 30, 2026, operating cash flow was −$1.5M; the largest uses were operating cash flow ($1.5M), other investing ($38K); besides operations, cash came from shares issued ($773K), other financing ($213K); the cash balance fell by $587K.
Operating cash flow was −$542K against net income of −$186K. The largest differences: receivables −$319K, inventory +$81K, income taxes payable −$80K.
Its cash conversion cycle was 221 days (receivables 21 + inventory 202 − payables 2).
Free cash flow
Capital allocation, year by year
Cash runway and the debt wall
BioScience Health Innovations is burning cash: its operations consume cash, a free cash flow of −$1.5M a year at the current rate against $712K of cash and investments: a runway of about 6 months before any new financing.
Where the cash came from and went
From profit to cash
| Quarter | Receivable days | Inventory days | Payable days | Cash conversion cycle |
|---|---|---|---|---|
| Q2 2026 | 21 | 202 | 2 | 221 |
| Q1 2026 | 29 | 205 | 2 | 232 |
| Q4 2025 | 14 | 50 | 1 | 63 |
| Q3 2025 | 18 | 107 | 3 | 122 |
| Q2 2025 | 13 | 31 | 2 | 41 |
| Q1 2025 | 7 | 37 | 3 | 41 |
| Q4 2024 | 10 | 17 | 3 | 24 |
| Q3 2024 | 5 | 26 | 5 | 26 |
Every quarter
| Quarter | Operating cash flow | Shares issued | Cash drawn (+) / kept (−) | Free cash flow |
|---|---|---|---|---|
| Q2 2026 | −$542K | $336K | $433K | −$542K |
| Q1 2026 | −$552K | $437K | −$483K | −$552K |
| Q4 2025 | −$101K | — | $477K | −$101K |
| Q3 2025 | −$340K | — | $160K | −$340K |
| Q2 2025 | $285K | — | −$271K | $285K |
| Q1 2025 | $328K | — | −$366K | $328K |
| Q4 2024 | −$50K | $455K | −$329K | −$50K |
| Q3 2024 | $52K | $175K | −$189K | $52K |
BioScience Health Innovations: income statement and cash flow
BioScience Health Innovations, Q2 2026: revenue $1.0M (-41% year over year), operating margin -21.0%. The chart follows the revenue to costs, profit and cash.
BioScience Health Innovations: every quarter, Q/Q and Y/Y → Open in the app
Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.